News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Bellerophon Therapeutics (BLPH) Reports Second Quarter 2017 Financial Results And Provides Business Update



8/7/2017 12:02:05 PM

  Life Sciences Jobs  
  • Newest Jobs - Last 24 Hours
  • California Jobs
  • Massachusetts Jobs
  • New Jersey Jobs
  • Maryland Jobs
  • Washington Jobs
  View More Jobs
SharePrint August 07, 2017 08:00 ET | Source: Bellerophon Therapeutics Inc. WARREN, N.J., Aug. 07, 2017 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (Nasdaq:BLPH), a clinical-stage biotherapeutics company, today provided a business update and reported financial results for the second quarter ended June 30, 2017.

“We continue to be encouraged with the progress of our Phase 3 clinical program in PAH, as well as Phase 2 programs in pulmonary hypertension associated with interstitial lung disease (PH-ILD) and chronic obstructive pulmonary disease (PH-COPD). In our INOvation-1 Phase 3 trial in PAH, we have now initiated 100 sites in 16 countries with around 50 patients already randomized,” stated Fabian Tenenbaum, Chief Executive Officer of Bellerophon Therapeutics. “We anticipate reporting top line results for this trial in 2018.”

Read at GlobeNewswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES